alert icon Coronavirus
Now scheduling COVID-19 vaccines for ages 12+, boosters and third doses
Schedule your appointment
COVID-19 vaccine FAQs

Going to a Cleveland Clinic location?
New visitation guidelines
Masks required for patients and visitors (even if you're vaccinated)

Department Cleveland Clinic Lou Ruvo Center for Brain Health
Primary Location Lou Ruvo Center for Brain Health - Las Vegas
Type of Doctor Adults Only
Languages English
Surgeon No
Locations Specialties & Treatments

Treatment & Services

  • Neurology
View all 1 Treatment & Services +

Specialty in Diseases & Conditions

  • Acute Disseminated Encephalomyelitis (ADEM)
  • Devic's Disease (Neuromyelitis Optica)
  • Multiple Sclerosis
  • Optic Neuritis
  • Transverse Myelitis
View all 5 Specialties +


Is Cleveland Clinic Nevada Part of Your Insurance?

For questions about accepted insurance plans for our Nevada locations and specific plan products including Medicare, please contact your insurance carrier directly.

View All Plans

About Carrie Hersh, DO

Carrie M. Hersh, DO, MSc, FAAN joined the faculty at Cleveland Clinic Lou Ruvo Center for Brain Health in August 2015 where she also serves as Assistant Professor of Neurology at Cleveland Clinic Lerner College of Medicine and directs the Multiple Sclerosis (MS) Health and Wellness Program at the Lou Ruvo Center for Brain Health. She completed a neuroimmunology fellowship at the Cleveland Clinic Mellen Center for MS Treatment and Research through a National MS Society Sylvia Lawry Award. She also earned a master’s degree in clinical research through the Clinical Research Scholars Program (CRSP) at Case Western Reserve University. She completed her adult neurology residency training at Cleveland Clinic and graduated medical school with honors from Nova Southeastern University-College of Osteopathic Medicine. She earned her BS degree in microbiology and neurobiology at University of Florida, graduating summa cum laude, and is a member of Phi Beta Kappa.

A patient advocate and proponent of shared decision making, Dr. Hersh specializes in multiple sclerosis and related neuroimmunological disorders. She is particularly interested in real-world evidence, outcomes-based research and comparative effectiveness studies. She serves as the principal investigator of multiple investigator-initiated studies and clinical trials investigating the effects of disease modifying therapies and wellness interventions on clinical, radiographic, and patient-reported outcomes. She is the lead investigator of the Multiple Sclerosis Partners Advancing Technology and Health Solutions program at Cleveland Clinic Lou Ruvo Center for Brain Health and serves on the study steering committee for the PCORI-funded DELIVER-MS clinical trial. Dr. Hersh is a frequent lecturer on multiple sclerosis and related disorders topics at national and international meetings and has authored more than 100 publications, including peer-reviewed scientific journal articles, invited reviews, editorials, abstracts, and book chapters. Currently, she is Chair of the Healthcare Advisory Council for the Multiple Sclerosis Association of America, Chair of the National MS Society’s regional Healthcare Provider Council, serves on the Board of Governors of the Consortium of MS Centers as Co-Chair of the Abstract Review Committee, and serves on numerous multiple sclerosis steering committees, expert panels, and advisory boards. 

Education & Professional Highlights

Education & Professional Highlights


Education & Fellowships

Graduate School - Case Western Reserve University
Clinical Research
Cleveland, OH USA

Fellowship - Cleveland Clinic
Cleveland, OH USA

Residency - Cleveland Clinic
Cleveland, OH USA

Internship - Cleveland Clinic
Internal Medicine
Cleveland, OH USA

Medical Education - Nova Southeastern University
Davie, FL USA

Undergraduate - University of Florida
Gainesville, FL USA

Professional Highlights

  • Peer Reviewed Publications:

    Hersh, CM. The effects of environmental challenges on nociception/orphanin FQ-induced anxiety. J Undergrad Res. 2005; 6(7).
  • Hersh, C, Rae-Grant, A. Extended-release dalfampridine in the management of MS-related walking impairment. Ther Adv Neurol Disord. 2012; 5(4):199-204. doi: 10.1177/1756285612447091. PMID: 22783369.
  • Hersh, CM, Cohen, JA. Alemtuzumab for the treatment of relapsing-remitting multiple sclerosis. Immunotherapy. 2014; 6(3): 249-259. doi: 10.2217/imt.14.7. PMID: 24762071.
  • Hersh, CM, Hara-Cleaver, C, Rudick, RA, Cohen, JA, Bermel, RA, Ontaneda, D. Experience with fingolimod in clinical practice. Int J Neurosci. 2015; 125(9):678-85. doi: 10.3109/00207454.2014.969839. PMID: 25271798.
  • Hersh, CM, Love, TE, Cohn, S, Hara-Cleaver, C, Bermel, RA, Fox, RJ, Cohen, JA, Ontaneda, D. Comparative efficacy and discontinuation of dimethyl fumarate and fingolimod in clinical practice at 12-month follow-up. Mult Scler Relat Disord. 2016 Nov; 10:44-52. doi: 10.1016/j.msard.2016.08.002. PMID: 27919497.
  • Hersh, CM, John, S, Subei, A, Willis, MA, Kosmorsky, G, Prayson, RA, Bhimraj, A. Optic neuropathy and stroke secondary to invasive Aspergillus in an immunocompetent patient. J Neuroophthalmol. 2016 Dec; 36(4):404-407. doi: 10.1097/WNO.0000000000000361. PMID: 27031126.
  • Hersh, CM, Love, TE, Bandyopadhyay, A, Cohn, S, Hara-Cleaver, C, Bermel, RA, Fox, RJ, Cohen, JA, Ontaneda, D. Comparative efficacy and discontinuation of dimethyl fumarate and fingolimod in clinical practice at 24-month follow-up. Mult Scler J Exp Transl Clin. 2017 Aug; 3(3):2055217317715485. doi: 10.1177/2055217317715485. PMID: 28890796.
  • Moss, B, Rensel, MR, Hersh, CM. Wellness and the role of comorbidities in multiple sclerosis. Neurotherapeutics. 2017 Oct; 14(4):999-1017. doi: 10.1007/s13311-017-0563-6. PMID: 28785958.
  • Vollmer, B, Ontaneda D, Bandyopadhyay, A, Cohn, S, Nair, K, Sillau, S, Bermel, R, Corboy, J, Fox, RJ, Vollmer, T, Cohen, JA, Alvarez, A, Hersh, CM. Discontinuation and comparative effectiveness of dimethyl fumarate and fingolimod in two centers. Neurol Clin Pract. 2018 Aug; 8(4):292-301. doi: 10.1212/CPJ.0000000000000487. PMID: 30140580.
  • Hua, LH, Hersh, CM, Morten, P, Kusel, J, Lin, F, Cave, J, Varga, S, Herrera, V, Ko, J. The impact of price reductions after loss of exclusivity in a cost-effective analysis: fingolimod versus intramuscularly-administered interferon beta-1a for the treatment of relapsing forms of multiple sclerosis. J Manag Care Spec Pharm. 2019 Apr; 25(4):490-498. doi: 10.18553/jmcp.2019.25.4.490. PMID: 30917079.
  • Vollmer, B, Ontaneda, D, Harris, H, Nair, K, Bermel, R, Corboy, J, Fox, RJ, Vollmer, T, Cohen, JA, Alvarez, A, Hersh, CM. Comparative discontinuation, effectiveness, and switching practices of dimethyl fumarate and fingolimod at 36-month follow-up. J Neurol Sci. 2019 Dec 15; 407:116498. doi:10.1016/j.jns.2019.116498. PMID: 31644992.
  • Conway, DS, Hersh, CM, Harris, HC, Hua, LH. Duration of natalizumab therapy and reasons for discontinuation in a multiple sclerosis population. Mult Scler J Exp Transl Clin. 2020 Jan 27; 6(1): 2055217320902488. doi: 10.1177/2055217320902488. PMID: 32064117.
  • Hua, LH, Harris, H, Conway, D, Hersh, CM. Disease activity outcomes with different washout periods after switching from natalizumab to an alternative disease-modifying therapy. J Neurol. 2020 Aug;267(8):2214-2220. doi: 10.1007/s00415-020-09816-1. PMID: 32270292.
  • Ontaneda, D, Tallantyre, EC, Raza, PC, Planchon, S, Nakamura, K, Miller, D, Hersh, C, Craner, M, Bale, C, Chaudhry, B, Gunzler, DD, Love, TE, Gerry, S, Coles, A, Cohen, JA, Evangelou, N. Determining the effectiveness of early intensive versus escalation approaches for the treatment of relapsing-remitting multiple sclerosis: The DELIVER-MS study protocol. Contemp Clin Trials. 2020 Aug;95:106009. doi: 10.1016/j.cct.2020.106009. PMID: 32320842.
  • Hauser SL, Bar-Or A, Cohen JA, Comi G, Correale J, Coyle PK, Cross AH, de Seze J, Leppert D, Montalban X, Selmaj K, Wiendl H, Kerloeguen C, Willi R, Li B, Kakarieka A, Tomic D, Goodyear A, Pingili R, Häring DA, Ramanathan K, Merschhemke M, Kappos L; ASCLEPIOS I and ASCLEPIOS II Trial Groups and Clinical Investigators: Hersh, C (I did not work closely with any of the listed authors on this publication). Ofatumumab versus teriflunomide in multiple sclerosis. N Engl J Med. 2020 Aug 6;383(6):546-557. doi: 10.1056/NEJMoa1917246.N Engl J Med. 2020. PMID: 32757523.
  • Mowry, E, Bermel, RA, Williams, JR, Benzinger, T, de Moor, C, Fisher, E, Hersh, CM, Hyland, MH, Izbudak, I, Jones, SE, Kieseier, BC, Kitzler HH, Krupp, L, Lui, YW, Montalban, X, Naismith, RT, Nicholas,, JA, Pellegrini, F, Rovira, A, Schulze, M, Tackenberg, B, Tintore, M, Tivarus, ME, Ziemssen, T, Rudick, RA. Harnessing real-world data to inform decision-making: multiple sclerosis partners advancing technology and health solutions (MS PATHS). Front Neurol. 2020 Aug 7;11:632. doi: 10.3389/fneur.2020.00632. PMID: 32849170.
  • Hersh, CM, Harris, H, Ayers, M, Conway, D. Effect of tobacco use on disease activity and DMT discontinuation in multiple sclerosis patients treated with dimethyl fumarate or fingolimod. Mult Scler J Exp Transl Clin. 2020 Oct 13;6(4):2055217320959815. doi: 10.1177/2055217320959815. PMID: 33110616.
  • Hua, LH, Hersh, CM, Tian, F, Mowry, EM, Fitzgerald, KC. Clinical characteristics of a large multi-center cohort of people with multiple sclerosis over age 60. Mult Scler Relat Disord. 2020 Nov 23;47:102637. doi: 10.1016/j.msard.2020.102637. PMID: 33276238.
  • Hersh, CM, Harris, H, Conway, D, Hua, LH. Impact of switching from natalizumab to moderate versus high efficacy DMT in clinical practice. Neurol Clin Pract. 2020 Dec 10 (6) e53-e65; doi: 10.1212/CPJ.0000000000000809. PMID: 33510948.Received “Notable This Week” and “Most Read Article” designations.
  • Morrison-Banks, E, Michtich, K, Hersh, CM. How the COVID-19 pandemic has changed multiple sclerosis clinical practice: results of a nationwide provider survey. Mult Scler Relat Disord. 2021 Mar 18;51:102913. doi: 10.1016/j.msard.2021.102913. PMID: 33839482.
  • Hersh, CM, Brook, RA, Beren, IA, Rohrbacker, NJ, Lebson, L, Henke, C, Phillips, A. The implications of suboptimal treatment outcomes with disease-modifying drugs in employees with multiple sclerosis. J Med Econ. 2021 Mar 19;24:1:479-486.doi: 10.1080/13696998.2021.1906013. PMID: 33739915.
  • Hersh, CM, Kieseier, B, deMoor, C, Miller, D, Campagnolo, D, Williams, JR, Fitzgerald, K, Xiong, K, McGinley, M, Hyland, M, Ruddick, R, Ziemssen, T, Koulinska, I. Impact of natalizumab on quality of life in a real-world cohort of patients with multiple sclerosis: results of MS PATHS. 2021 Apr 15;7(2). doi: 10.1177/20552173211004634.


  • Psychiatry and Neurology - Neurology

Awards & Honors

  • 2001 University of Florida Honors Program
  • 2002 Phi Eta Sigma Honor Society, UF
  • 2002 National Society of Collegiate Scholars
  • 2002 Golden Key International Honor Society, UF
  • 2004 National Dean’s List
  • 2004 National Society of Collegiate Scholars Merit Award, UF
  • 2004 Presidential Recognition, UF
  • 2004 Chancellor’s List, UF
  • 2004 University Scholars Program, UF
  • 2004 Phi Kappa Phi Honor Society, UF
  • 2004 Phi Beta Kappa, UF
  • 2005-2009 Dean’s List, NSU
  • 2006 Sigma Sigma Phi Honor Society, NSU
  • 2009 Psi Sigma Alpha National Osteopathic Honor Society, NSU
  • 2012 7th Annual MASTER MS Fellowship Program
  • 2014 Consortium of MS Centers (CMSC) Scholarship Award
  • 2015 American Academy of Neurology (AAN) Fellows Scholarship Award
  • 2015 Neurological Institute Research Day Clinical Fellow Award, CCF
  • 2016 Travel Grant Award, European Committee for Treatment and Research in MS (ECTRIMS) 2016
  • 2016 Top Score Poster, ECTRIMS 2016
  • 2016 Top Score Poster, ECTRIMS 2016
  • 2016 Editor’s Choice for original research, Multiple Sclerosis and Related Disorders journal article “Comparative efficacy and discontinuation of dimethyl fumarate andfingolimod in clinical practice at 12-month follow-up”
  • 2017 Travel Grant Award, ECTRIMS 2017
  • 2018 Healthcare Headliner Award in Research/Science, Vegas Inc.
  • 2018 Top Score Poster, ECTRIMS 2018
  • 2019 Top Score Poster, ECTRIMS 2019
  • 2020 Fellow of the American Academy of Neurology (FAAN)


  • Consortium of Multiple Sclerosis Centers
  • National Multiple Sclerosis Society
  • American Academy of Neurology
Research & Publications

Research & Publications

See publications for Carrie Hersh, DO.

(Disclaimer: This search is powered by PubMed, a service of the U.S. National Library of Medicine. PubMed is a third-party website with no affiliation with Cleveland Clinic.)

Industry Relationships

Industry Relationships

Cleveland Clinic physicians and scientists may collaborate with the pharmaceutical or medical device industries to help develop medical breakthroughs or provide medical expertise or education. Cleveland Clinic strives to make scientific advances that will benefit patient care and support outside relationships that promise public benefit. In order for the discoveries of Cleveland Clinic physicians' and scientists' laboratories and investigations to benefit the public, these discoveries must be commercialized in partnership with industry. As experts in their fields, Cleveland Clinic physicians and scientists are often sought after by industry to consult, provide expertise and education.

To assure professional and commercial integrity in such matters, Cleveland Clinic maintains a program that reviews these collaborations and, when appropriate, puts measures in place to minimize bias that may result from ties to industry. Cleveland Clinic publicly discloses the names of companies when (i) its physicians/scientists receive $5,000 or more per year (or, in rare cases, equity or stock options) for speaking and consulting, (ii) its physicians/scientists serve as a fiduciary, (iii) its physicians/scientists receive or have the right to receive royalties or (iv) its physicians/ scientists hold any equity interest for the physician's/scientist's role as inventor, discoverer, developer, founder or consultant.* In publicly disclosing this information, Cleveland Clinic tries to provide information as accurately as possible about its physicians' and scientists' connections with industry.

As of 9/2/2021, Dr. Hersh has reported the financial relationships with the companies listed below. In general, patients should feel free to contact their doctor about any of the relationships and how the relationships are overseen by Cleveland Clinic. To learn more about Cleveland Clinic's policies on collaborations with industry and innovation management, go to our Integrity in Innovation page.

Consulting and/or Speaking. Dr. Hersh receives fees of $5,000 or more per year as a paid consultant, speaker or member of an advisory committee for the following companies:

  • Multiple Sclerosis Association of America

Public Health Service-Reportable Financial Conflicts of Interest. Cleveland Clinic scientists and physicians engage in basic, translational and clinical research activities, working to solve health problems, enhance patient care and improve quality of life for patients. Interactions with industry are essential to bringing the researchers' discoveries to the public, but can present the potential for conflicts of interest related to their research activities. Click here to view a listing of instances where Cleveland Clinic has identified a Public Health Service (PHS)-Reportable Financial Conflict of Interest and has put measures in place to ensure that, to the extent possible, the design, conduct and reporting of the research is free from bias.

* Cleveland Clinic physicians and scientists subscribe to the guidance presented in the PhRMA Code on Interactions with Healthcare Professionals and the AdvaMed Code of Ethics on Interactions with Health Care Professionals. As such, gifts of substantial value are generally prohibited.

Patient Satisfaction Reviews

153 Patient Satisfaction Reviews

The Patient Satisfaction Rating is an average of all responses to the care provider related questions shown below from our nationally-recognized Press Ganey Patient Satisfaction Survey. Patients that are treated in outpatient or hospital environments may receive different surveys, and the volume of responses will vary by question.

Responses are measured on a scale of 1 to 5 with 5 being the best score.

The comments are submitted by patients and reflect their views and opinions. The comments are not endorsed by and do not necessarily reflect the views of Cleveland Clinic.

Overall Star Ratings
5 out of 5
Explains 4.9
Courtesy, Respect & Concern 5
Patient Rating of Doctor 5

29 Patient Comments

Reviewed on Sep 22, 2021

Dr. Hersh was very attentive. When I stated I was having unusual stiffness in my left leg, she took extra time to look at my MRI imaging again. I appreciate her double checking with care during this visit, it meant a lot to me.

Reviewed on Sep 21, 2021

Dr. Carrie Hersh is always professional, super nice and caring! She strives to improve the quality of my life and reduce the impact of my disability everytime I see her! I wish every doctor in the U.S.A. had the genuine care/compassion for their patients that Dr.Hersh has for hers!

Reviewed on Sep 21, 2021

As stated in previous comment about Dr Carrie Hersh, she is a wonderful, caring doctor. I truly feel that she wants to better my life and ease the struggles that my condition causes.

Reviewed on Aug 31, 2021

Dr. Hersh is always at the top of her game whenever I have an appointment.

Reviewed on Jul 14, 2021

Dr Hersh is so amazing. So grateful for her and her knowledge.

Reviewed on Jul 13, 2021

She's a great doctor

Reviewed on May 21, 2021

Dr. Carrie Hirsh is the best.

Reviewed on Apr 30, 2021

Dr. Hersh always takes her time to explain everything in a way that is easy to understand. She is very personable and it is easy to make a connection with her.

Reviewed on Apr 30, 2021

Dr Hirsh gave me the most thorough examination I have ever had! She explained her opinions and gave us a sense of trust in her knowledge.

Reviewed on Mar 31, 2021

I love Dr. Hersh! She is the best of the best!

Reviewed on Mar 31, 2021

Lou Ruvo Cleveland Clinic is an exceptional facility with the most qualified doctors, staff and volunteers! BRAVO !!!!!

Reviewed on Mar 31, 2021

Dr.Hersh is a very understanding doctor that realizes that with my multiple sclerosis disease, I can be extremely forgetful about my medication etc. I am very grateful that I have an excellent doctor reminding me of bloodwork and needed MRI appointments

Reviewed on Mar 31, 2021

Dr. Hersh is an exceptional provider. During all my visit, Dr. Hersh has been very thorough and straightforward in communicating my condition with me.

Reviewed on Mar 30, 2021

Dr. Hersh was wonderful.!!!!!

Reviewed on Mar 10, 2021

Dr. is very knowledgeable and explains things in a through manner.

Reviewed on Mar 9, 2021

Dr. Hersh is very professional and gives a great deal of care to her patients. She is also extremely knowledgeable.

Reviewed on Mar 5, 2021

Dr Hersh is the absolute best Dr I've ever had

Reviewed on Mar 5, 2021

Dr Hersh is very professional with all my concerns. Glad to have as my MS doctor Thank you

Reviewed on Mar 2, 2021

Dr. Hersh is truly my partner in my care. She listens and understands me. I am so grateful to have her as my doctor.

Reviewed on Jan 26, 2021

Dr Hersh is the best doctor I have seen. She is very knowledgeable and caring. You do not feel that you are just a number with her.

Reviewed on Dec 15, 2020

Dr Hersh was very thorough in every question that was ask, went above and beyond as a Dr..very courteous..

Reviewed on Dec 9, 2020

Dr. Hirsch did an excellent job of keeping me informed about everything pertaining to my condition. She is an excellent addition to your staff.

Reviewed on Dec 1, 2020

I always feel comfortable with Dr Hersh which is big for me because I have a fear of doctors!

Reviewed on Nov 18, 2020

The clinic, staff and Dr Hersh treated me with the up most Respect & Kindness while exhibiting Professionalism.

Reviewed on Nov 18, 2020

Absolutely Love my Doctor, Dr. Hersh.

Reviewed on Nov 4, 2020

I tell people everywhere I go how awesome Dr Hersh and the Cleveland Clinic are. They really care.

Reviewed on Nov 3, 2020

Cleveland clinic far surpasses any medical facility I've ever dealt with in terms of professionalism, care, expertise, and follow up. I wish every medical facility would copy your company's mission. your next venture should be to provide outreach to medical facilities in the community that do t provide the same level of care and help providers work together to better assess and treat illness.

Reviewed on Oct 28, 2020

I really like my care providers decisions and I care about the help of offering me to go to physical therapy at the clinic to help me with my legs so I'll be able to walk and use the equipment at my house and to get stronger once again

Reviewed on Oct 21, 2020

dr hersh is fantasy- feel lucky to have her

Related Videos Featuring Carrie Hersh, DO

Related Videos Featuring Carrie Hersh, DO

Back to Top